The Latest Cardiac and Vascular News
NASDAQ: CORV TSX: CORV VANCOUVER, Dec. 24, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Brinavess™ (vernakalant IV), an anti-arrhythmic drug for the conversion of […]
NASDAQ: CORV TSX: CORV Post Hoc Analysis of Subset of Patients Treated in the Emergency Department Setting Safety Outcomes of Interest Observed in Less Than 1% Cases; No Deaths Reported Greater Than 70% of Atrial Fibrillation Episodes Successfully Converted to Sinus Rhythm in a Median Time of 12 Minutes VANCOUVER, Nov. 18, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) […]
VANCOUVER, July 25, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for Brinavess™ (vernakalant hydrochloride, IV), an antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation […]
VANCOUVER, Feb. 7, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced the presentation of clinical data highlighting the low rate of hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), at the Belgian […]
VANCOUVER, Oct. 29, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV /TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that it has received independent regulatory and legal opinions that Brinavess® (vernakalant hydrochloride, IV) may qualify for up to a 5-year patent extension from the U.S. Patent and Trademark Office (USPTO). […]
VANCOUVER, Oct. 23, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV /TSX: CORV), a specialty pharmaceutical company focused on providing high-quality brands to acute care physicians and patients, today announced that, based on productive pre-NDA discussions with the U.S. Food and Drug Administration (FDA), Correvio plans to resubmit the Brinavess® (vernakalant hydrochloride, IV) New Drug […]
VANCOUVER, Aug. 16, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today reported positive data highlighting reduced hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset […]
VANCOUVER, June 11, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today announced that it has received a response from the U.S. Food and Drug Administration (FDA) regarding the regulatory path forward in the US […]
VANCOUVER, June 6, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the Brinavess®study, titled “Vernakalant in hospital emergency practice: safety and effectiveness,” published by José Carbajosa Dalmau (Alicante, Spain), was awarded first prize for the best work published during the year 2017 in the […]
